This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections.